Characterization of the Expression of the RNA Binding Protein eIF4G1 and Its Clinicopathological Correlation with Serous Ovarian Cancer.
BACKGROUND
Ovarian cancer is the most lethal type of malignant tumor in gynecological cancers and is associated with a high percentage of late diagnosis and chemotherapy resistance. Thus, it is urgent to identify a tumor marker or a molecular target that allows early detection and effective treatment. RNA-binding proteins (RBPs) are crucial in various cellular processes at the post-transcriptional level. The eukaryotic translation initiation factor 4 gamma, 1(eIF4G1), an RNA-binding protein, facilitates the recruitment of mRNA to the ribosome, which is a rate-limiting step during the initiation phase of protein synthesis. However, little is known regarding the characteristics of eIF4G1 expression and its clinical significance in ovarian cancer. Therefore, we propose to investigate the expression and clinicopathological significance of eIF4G1 in ovarian cancer patients.


METHODS
We performed Real-time PCR in 40 fresh serous ovarian cancer tissues and 27 normal ovarian surface epithelial cell specimens to assess eIF4G1mRNA expression. Immunohistochemistry (IHC) was used to examine the expression of eIF4G1 at the protein level in 134 patients with serous ovarian cancer and 18 normal ovarian tissues. Statistical analysis was conducted to determine the correlation of the eIF4G1 protein levels with the clinicopathological characteristics and prognosis in ovarian cancer.


RESULTS
The expression of eIF4G1 was upregulated in serous ovarian cancer tissues at both the mRNA (P = 0.0375) and the protein (P = 0.0007) levels. The eIF4G1 expression was significantly correlated with the clinical tumor stage (P = 0.0004) and omentum metastasis (P = 0.024). Moreover, patients with low eIF4G1 protein expression had a longer overall survival time (P = 0.026).


CONCLUSIONS
These data revealed that eIF4G1 is markedly expressed in serous ovarian cancer and that upregulation of the eIF4G1 protein expression is significantly associated with an advanced tumor stage. Besides, the patients with lower expression of eIF4G1 tend to have a longer overall survival time. Thus, eIF4G1 may contribute to the occurrence and metastasis of ovarian cancer and can serve as a potential therapeutic target for the treatment of ovarian cancer.
Department of Obstetrics and Gynecology, Research Institute of Surgery, Daping Hospital, Third Military Medical University, Chongqing, China.
Lanfang
L
Li
Department of Pathology, Research Institute of Surgery, Daping Hospital, Third Military Medical University, Chongqing, China.
Qingya
Q
Luo
Department of Obstetrics and Gynecology, Research Institute of Surgery, Daping Hospital, Third Military Medical University, Chongqing, China.
Zhe
Z
Xie
Department of Obstetrics and Gynecology, Research Institute of Surgery, Daping Hospital, Third Military Medical University, Chongqing, China.
Guiqin
G
Li
Department of Pathology, Research Institute of Surgery, Daping Hospital, Third Military Medical University, Chongqing, China.
Chengyi
C
Mao
Department of Obstetrics and Gynecology, Research Institute of Surgery, Daping Hospital, Third Military Medical University, Chongqing, China.
Yi
Y
Liu
Department of Biochemistry, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences (CAMS) & Peking Union Medical College (PUMC), Beijing 100005, PR China.
Xin
X
Wen
Department of Obstetrics and Gynecology, Research Institute of Surgery, Daping Hospital, Third Military Medical University, Chongqing, China.
Na
N
Yin
Department of General Surgery, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
Jianzhong
J
Cao
Department of Obstetrics and Gynecology, Research Institute of Surgery, Daping Hospital, Third Military Medical University, Chongqing, China.
Jing
J
Wang
Department of Obstetrics and Gynecology, Research Institute of Surgery, Daping Hospital, Third Military Medical University, Chongqing, China.
Li
L
Li
The Ohio State University of Comprehensive Cancer Center, Columbus, Oh 43210, United States of America.
Jianhua
J
Yu
Department of Biochemistry, Institute of Basic Medical Sciences, Chinese Academy of Medical Sciences (CAMS) & Peking Union Medical College (PUMC), Beijing 100005, PR China.
Fang
F
Wang
Department of Obstetrics and Gynecology, Research Institute of Surgery, Daping Hospital, Third Military Medical University, Chongqing, China.
Ping
P
Yi
Biol Cell. 2003 May-Jun;95(3-4):141-56
12867079
Cancer Cell. 2009 Dec 8;16(6):521-32
19962670
RNA Biol. 2006 Jul;3(3):101-9
17114948
CA Cancer J Clin. 2011 Mar-Apr;61(2):69-90
21296855
Cancer Res. 2013 Aug 15;73(16):5016-28
23824740
Int J Cancer. 2002 Mar 10;98(2):181-5
11857405
Am J Hum Genet. 2011 Sep 9;89(3):398-406
21907011
Cell Signal. 2014 Sep;26(9):1878-87
24815186
Int J Gynecol Cancer. 2014 Jun;24(5):908-15
24844222
Clin Cancer Res. 2009 Jul 1;15(13):4336-47
19458052
Cell. 2012 Jun 8;149(6):1393-406
22658674
Cell Res. 2007 Jul;17(7):581-90
17621309
Nat Rev Genet. 2010 Jan;11(1):75-87
20019688
Gastroenterology. 2010 Jan;138(1):231-40.e1-5
19686745
Cancer Biol Ther. 2014 Jan;15(1):108-18
24153116
Nat Cell Biol. 2009 Jul;11(7):903-8
19525934
Nat Rev Genet. 2013 Apr;14(4):275-87
23478349
Hepatology. 2014 May;59(5):1900-11
24395596
Oncotarget. 2015 Aug 21;6(24):20636-49
26010068
Oncotarget. 2015 Feb 28;6(6):4315-29
25717031
Nature. 2015 Nov 26;527(7579):S217
26605761
CA Cancer J Clin. 2016 Mar-Apr;66(2):115-32
26808342
Proc Natl Acad Sci U S A. 2015 Jul 28;112(30):E4036-45
26170285
Science. 2015 Jun 26;348(6242):1486-8
26113725
Proc Natl Acad Sci U S A. 2012 Nov 13;109(46):18767-72
23112151
Mutat Res. 2015 Jan;771:6-12
25771974
Nat Struct Mol Biol. 2012 Jun 05;19(6):568-76
22664984
Nat Rev Mol Cell Biol. 2010 Feb;11(2):113-27
20094052
CA Cancer J Clin. 2014 Jan-Feb;64(1):9-29
24399786
Nat Rev Mol Cell Biol. 2002 Mar;3(3):195-205
11994740